Xenon Pharmaceuticals Closes Upsized Offering, Nets $707.7M
XENE has more than doubled off its 52-week low of $26.74 on elevated volume (2.3× avg).
Summary
Xenon Pharmaceuticals has successfully closed its underwritten public offering, securing approximately $707.7 million in net proceeds. This final amount is notably higher than the $650.0 million previously announced, reflecting the full exercise of the underwriters' option for additional shares. This capital raise follows the highly positive topline results from its Phase 3 X-TOLE2 study of azetukalner, reported on March 9. The offering, priced at $57.00 per share, significantly bolsters the company's liquidity, providing substantial funding for general corporate purposes, including the advancement of its clinical pipeline. The successful completion of this upsized financing event strengthens Xenon's financial position as it progresses its lead drug candidate.
At the time of this announcement, XENE was trading at $57.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $26.74 to $63.95. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.